They also reported that there was no difference in the expression

They also reported that there was no difference in the expression of TRPM8 in urinary bladder afferent neurons between control and bladder outlet obstruction rats.48 Shibata et al.49 also reported that dichotomizing afferents of L6-S1 dorsal root ganglion neurons that innervate the skin and bladder were constantly observed with retrograde neuron tracers in rats. In situ hybridization experiments revealed that approximately 8.0% of the double-labeled cells expressed transient receptor

potential channel melastatin member 8 (TRPM8) transcripts in the dorsal root ganglia. Cold and menthol stimuli to the skin generated bladder nerve responses conducted through dichotomizing axons, which significantly decreased in the presence of the TRPM8 blocker BCTC. Taken together, they concluded that TRPM8-expressing Wnt inhibitors clinical trials sensory neurons with dichotomizing axons projecting to the skin and bladder may be responsible for the urinary urgency evoked by cold stimuli. Cold, heat, pain, and touch sensations on the skin are passed to the thalamus via the dorsal root and spinothalamic tract (Fig. 9). In this pathway, there must be some type of interaction with the micturition

control system. The adrenergic nervous system, unmyelinated c-fibers, and TRPM8 may play important roles in this pathway (Fig. 9).15,17,47–49 Further studies are required to clarify the mechanism of the cold stress-induced increase in urinary frequency and the roles of TRPM8 in the micturition control system. The authors of this paper have no financial or commercial interests to disclose. “
“Objectives: The clinical efficacy and safety of 75 mg/day of naftopidil, an α1-adrenargic receptor antagonist, was assessed DAPT mouse mafosfamide in patients with benign prostatic hyperplasia (BPH). Methods: A total of 28 patients (mean age, 71.1 years; range, 46–86 years) with BPH were studied. Inclusion criteria were: (i) International

Prostate Symptom Score (IPSS) ≥8; and (ii) quality of life (QOL) index ≥3. IPSS, QOL index, Overactive Bladder Symptom Score (OABSS), and bladder diary (urinary frequency in daytime and nighttime, frequency of urinary incontinence and urgency) were evaluated before and 4 weeks after treatment with naftopidil at 75 mg/day. Results: Total IPSS and QOL index were significantly decreased after treatment. Total OABSS tended to decrease after treatment, with significant improvements in the “urgency” parameter. From the bladder diary, urinary frequency in daytime and nighttime and frequency of urgency were significantly decreased after treatment. Total IPSS and QOL index in patients with previous treatment were significantly improved after treatment, with significant improvements in the “incomplete emptying,”“poor flow” and “nocturia” parameters of IPSS. One case with a mild adverse effect of dizziness was encountered. Conclusion: These results suggest that administration of naftopidil at 75 mg/day was safe and effective for patients with BPH, regardless of the presence of previous treatment.

[64] Examples of

hsp-based therapeutics in cancer trials

[64] Examples of

hsp-based therapeutics in cancer trials are detailed in Table 3. To date, one hsp vaccine, Vitespen, is licensed and marketed. The hsp gp96, the master chaperone for Toll-like receptors[65], is the major component of Vitespen. Chaperoning by gp96 Belnacasan purchase increases uptake over unchaperoned peptides in vitro by two orders of magnitude and immunization of mice with 5 ng gp96–peptide complexes, results in generation of a peptide-specific CD4+ T-cell response.[66] In April 2008, Vitespen was approved in Russia as a patient-specific adjuvant treatment of kidney cancer for individuals at intermediate-risk for disease recurrence. Outside Russia, Vitespen is an investigational vaccine designed to treat cancer with the intent of minimizing side-effects. It has been studied extensively in clinical trials in Phase I and II settings, demonstrating efficacy in some but not all trials. Phase III studies have been

completed in which over 1300 patients with renal cell carcinoma or malignant melanoma have been treated. Essentially neither toxicity nor autoimmunity induced by Vitespen was observed.[67] Marketed (Russia) Disease-dependent Phase II and III Although pre-clinical studies with Vitespen were promising, AG-014699 chemical structure clinical studies show limited efficacy.[68] This outcome may be a consequence of differences in the hsp content of Vitespen used for 17-DMAG (Alvespimycin) HCl initial in vivo models compared with the vaccine used for clinical trials.[69] Pre-clinical studies reported utilised vaccines containing gp96 or hsp70, while clinical studies utilised vaccine containing only gp96. Critically, gp96 and hsp70 have distinct functions as endoplasmic reticulum (ER) luminal and cytoplasmic chaperones, respectively, and thus bind distinct client proteins. Heat-shock protein 70 binds a variety of cytoplasmic proteins and isolation of this hsp from tumour cells will result in the purification of intact hsp–client protein complexes. In contrast, gp96 binds membrane proteins such as

integrins and Toll-like receptors and is essential for chaperoning peptides in the ER.[70] As the clinical production processes used do not contain detergents,[71] peptides bound to gp96 in Vitespen are unlikely to result from tumour client proteins. Hence differences between the bound peptides in gp96 isolated from the homogeneous tumour tissue in the animal models and the heterogeneous tumour tissue from patients in the clinical trials may also account for the limited efficacy reported for Vitespen.[68] Other key issues concerning the future development of such a vaccine are the correct and effective dose of hsp, and which patients to target. Other hsp provide alternatives to gp96 for cancer vaccine development. Vaccination with hsp70 derived from the Meth A sarcoma, established dose-dependent immunity to challenge with Meth A sarcoma in mice.

Amongst the upregulated genes, the p62 (also known as sequestosom

Amongst the upregulated genes, the p62 (also known as sequestosome 1) (SQSTM1) is an adaptor protein that has a role in inflammation, neurogenesis, osteoclastogeneis, adipogenesis and T-cell differentiation [21]. Our data indicated that p62 is induced by TLR-2 and NOD-1 activation at both mRNA and protein levels. Elucidating the pathways that control selleck products p62 levels in MSC will add another layer of detail to our understanding of the cell differentiation cascades in which p62

is involved. In addition to p62, VEGF and CXCL-10 were upregulated in response to NOD-1 and TLR-2 signalling. Human MSC released VEGF in response to TLR-2 and NOD-1 ligands as a potentially beneficial paracrine response. It will be interesting to investigate which mechanisms are involved in VEGF upregulation and secretion in MSC. Notably, previous studies have suggested a direct contribution of MSC to the blood vessel formation, as differentiation of MSC

into endothelial cells has been demonstrated [22, 23]. In contrast to NOD-1, TLR-2 signalling Doramapimod also upregulated the expression of several important genes such as interleukin-1 receptor-associated kinase 2 (IRAK-2), involved in TLR signalling, NOTCH-1 and Gal-3 involved in innate and adaptive immunity. Notably, Notch pathway is highly conserved in evolution and is generally involved in cell fate decisions during cell differentiation [24]. A recent study showed that the inhibition of Notch signalling in MSC can hinder their suppressive activity on T-cell proliferation [13]. In addition to binding to glycan structures that are expressed by host cells, galectins can also recognize β-galactoside carbohydrates that are common structures on many pathogens [25], and therefore they are considered as a soluble pathogen recognition receptor. Within

the immune system, galectins are expressed Urease by virtually all immune cells, either constitutively or in an inducible fashion [17]. Also, they can be expressed by a spectrum of normal and tumour cells. As found in this study, Gal-3 is constitutively expressed by MSC and upregulated in response to TLR-2 ligation. Of note, high levels of Gal-3 protein are found in MSC culture supernatants; thus, it may participate in extra cellular matrix (ECM)-cell interactions and modulation of surrounding immune cells. Results from knockdown experiments showed that the immunosuppressive effects of MSC on T cells was lower than that from cells expressing Gal-3, suggesting a possible involvement of Gal-3 in MSC immunosuppressive function. This observation would fit with the demonstrated inhibitory effect of Gal-3 on T-cell proliferation [19, 20]. Also, a more recent study showed that tumour-associated Gal-3 contributes to tumour immune escapes by inhibiting the function of tumour-reactive T cells [26]. Some studies demonstrated that the MSC immunoregulatory properties are at least in part mediated by the production of cytokines, such TGF-β and hepatocyte growth factors [27].

The presence of a significantly increased number of TCR Vβ8+ lymp

The presence of a significantly increased number of TCR Vβ8+ lymphocytes in Peyer’s patches upon chronic DSS-induced colitis

is associated with aggravated mucosal inflammation, as determined by significantly increased weight loss and MEICS score of Bim–/– compared to wild-type mice. Data from spleen weight, colon length and histological score confirmed this suggestion. Interestingly, TCR Vβ8+ lymphocytes can bind SEB. Wild-type mice treated with a single intrarectal instillation of SEB displayed a time- and dose-dependent colonic inflammation which was further increased significantly in ovalbumin transgenic mice with 95% TCR Vβ8+ lymphocytes [24]. Enhanced expression of the pro-survival proteins BCL-2 and BCL-xL was determined in www.selleckchem.com/products/yap-tead-inhibitor-1-peptide-17.html lamina propria T cells of patients with CD when compared with controls. Lamina propria T cells in CD patients show activation of the STAT-3 signalling pathway mediated by IL-6. Activation of STAT-3 is followed by the induction of anti-apoptotic genes such as BCL-2 and BCL-xL [14]. Resistance of CD T cells to multiple apoptotic signals is associated with increased BCL-2 expression. An abnormal BCL-2 expression in lamina propria mononuclear cells from patients with CD was demonstrated [15]. A significantly higher BCL-2/Bax ratio in CD mucosa compared to controls was reported [16]. These data are consistent

with a recent report showing significant resistance to Fas-induced apoptosis of peripheral T cells from CD patients

[17]. The same immunological consequence resulting from the extended lifespan of antigen-primed T cells is see more supported by a reduced survival or function of Treg cells. Apoptosis is elevated strongly in mucosal and peripheral CD4+CD25highforkhead box protein 3 (FoxP3)+ Treg cells of patients with IBD [25]. Failure of the apoptotic mechanism of lymphocyte control can lead to the development of autoimmunity or lymphoma. Bim deficiency perturbed thymic T cell development. As expected for the loss of a pro-apoptotic molecule, C-X-C chemokine receptor type 7 (CXCR-7) the numbers of both the CD4−8− pro-T cells and the mature T cells (CD4+8− and CD4−8+) were two- to threefold higher than in wild-type animals. Surprisingly, however, the CD4+8+ pre-T cells, the predominant thymic subpopulation, were only half the normal level [8]. Interestingly, we observed rectum prolapses in Bim–/– animals. The trigger for the appearance of prolapses was not investigated in this work. As described for mice homozygous for Il10tm1Cgn, targeted mutations leading to altered lymphocyte populations are most likely to be involved in prolapse formation. As described for IL-10–/– mice, animal housing conditions and the microbiome influence prolapse development. However, our mice were housed in IVC in a SPF facility where a less developed microbiome could be expected. We found significantly increased inflammation in Bim–/– animals compared to wild-type mice upon chronic DSS-induced colitis.

48–50 Studies in our laboratory using an animal model have shown

48–50 Studies in our laboratory using an animal model have shown that viral infection of the placenta triggers a fetal inflammatory response similar to the one observed in FIRS, even though the virus is not able to reach the fetus.51 In the case of human FIRS, these cytokines have been shown to affect the CNS and the selleckchem circulatory system.50,52 Interestingly, we found fetal morphologic abnormalities in the animals, including ventriculomegaly and hemorrhages, which may be caused by fetal pro-inflammatory cytokines such as Il-1, TNFα, MCP-1, MIP1-β and INF-γ. Beyond morphological effects on the fetal brain, the presence of FIRS increases the future risk for

autism, schizophrenia, neurosensorial deficits

and psychosis induced in selleck chemical the neonatal period.53–55 Moreover, there is evidence that the fetal immune response may predispose to diseases in adulthood.49 Because of this, we propose that an inflammatory response in the placenta, which alters the cytokine balance in the fetus, may affect the normal development of the fetal immune system leading to anomalous responses during childhood or later in life (Fig. 2). One example of this is the differential responses in children to vaccination or the development of allergies. Antenatal infections can have a significant impact on later vaccine responses. We can observe this type of outcome in other conditions associated with placental infection, such as malaria. A few studies GPX6 suggest that surviving infants with placental malaria may suffer adverse neurodevelopmental sequelae and may have abnormal responses to a later parasitic infection.56 In all

these cases the parasite did not reach the placenta, but the inflammatory process in the placenta affected the normal fetal development.57 The number of infectious diseases has increased during the past two decades and will continue to increase as result of the changes in the behavior of the human population.58 As travel to and from different regions of the world increases, the appearance of new pathogens will also increase. The challenge to determine whether each new pathogen represents a major risk for pregnancy will become more and more difficult if our understanding of the immunology of pregnancy does not evolve from where it is today. In addition, when evaluating the maternal responses to the pathogen, it is important to know the placental response to the pathogen; because, as indicated earlier, some microorganisms may not directly affect the pregnancy but could ‘sensitize’ the mother and the fetus to additional pathogens. In those cases, prophylaxis is required, and the earlier the better. The mantra is first do no harm. Therefore, the risk-benefit of vaccination during all stages of pregnancy should be carefully evaluated.

Balanced frequencies are often observed for the centromeric KIR A

Balanced frequencies are often observed for the centromeric KIR A and B haplotypes; the frequency of Cen-A (i.e. characterized by the presence of KIR2DL3, KIR2DP1 and KIR2DL1) in most populations worldwide

is ∼ 50–60%, roughly that which is observed for the extended A haplotype. The notable exception is within East Asian populations,110,111,126 where the frequency of the Kinase Inhibitor Library datasheet centromeric B haplotype loci KIR2DL2 and KIR2DS2 is generally very low and Cen-A is observed at frequencies greater than 80%; the frequency of the extended (centromeric and telomeric) A haplotype also tends to be highest in these populations. It is interesting to note, however, that these exceptionally high Cen-A frequencies are generally not observed in Amerindian populations,112 suggesting that this shift occurred within East Asia subsequent to the differentiation selleck chemicals llc of the Amerindians from these populations. Although the loci associated with the full-length motif Cen-B1 (i.e. characterized by the presence of KIR2DL2, KIR2DS2, KIR2DL5, KIR2DS3/S5, KIR2DP1 and KIR2DL1) are very common within Africa,110,112,127 the much shorter

Cen-B2 (i.e. characterized by the presence of the framework genes in addition to KIR2DL2 and KIR2DS2) is observed primarily outside Africa, and this motif largely replaces Cen-B1 in some populations outside Africa (J. Hollenbach, unpublished results). However, there is no clear pattern or gradient associated with this motif, which appears

to be distributed somewhat sporadically across several world regions. African populations in general exhibit substantially greater haplotypic diversity within the centromeric KIR region relative to other world regions. The telomeric portion of the KIR is characterized by a Farnesyltransferase pattern of variation more closely related to population demographics. As previously noted, the stimulatory KIR3DS1 is found at much lower frequencies in African populations relative to most other world populations;112,128 its frequency increases with geographic distance from Africa.110 Although the African populations exhibit some of the highest frequencies for the centromeric B haplotype loci, the frequency of all telomeric B haplotype activating loci is in general very low in African populations. However, whereas the overall frequency of the extended B haplotype is comparatively low among the Asian populations, extended B haplotype frequencies are relatively high in the African populations. Other world populations generally range between these extremes. It is striking, however, that despite this variation, the worldwide frequency of A and B haplotype heterozygosity is generally stable, with an average frequency of 44%, suggesting that there is a population-level advantage in maintaining these balanced frequencies.

The relative importance of such conformational changes for select

The relative importance of such conformational changes for selection of the CD4 T-cell repertoire is not known but a recent study by Nabel and colleagues suggests that different vaccine vectors www.selleckchem.com/products/obeticholic-acid.html carrying identical proteins can generate peptides with alternative conformations within

MHC class I molecules and elicit distinct T-cell responses after vaccination.66 Understanding the mechanisms of immune protection after vaccination is central to the rational design of all future vaccines. Vaccine adjuvants, a central component of protein subunit vaccines, have been traditionally optimized based on their capacity to increase the magnitude of the adaptive immune response. It is, however,

clear that adjuvants also control some more qualitative aspects of the immune response that could play an important role in determining vaccine efficacy, such as the specificity and clonotypic diversity of the responding CD4 T-cell compartment. A precise understanding of the mechanisms by which vaccine adjuvants modulate the immune repertoire of the adaptive immune response should lead, in the future, to the development of improved vaccines. The authors BGB324 manufacturer have nothing to disclose. This work was supported by NIH grant U19 A162627, the American Cancer Society and the Medical College of Wisconsin Cancer Center. C.B. was supported by a fellowship from FWF – the Austrian Science Fund. “
“Regulatory T cells (Tregs) are known to play an immunosuppressive role in the response of contact hypersensitivity (CHS) but

neither the dynamics of Tregs during the CHS response nor the exaggerated inflammatory response after depletion of Tregs has been characterized in details. In this study we show that the number of Tregs in the challenged tissue peak at the same time as the ear swelling reaches its maximum day 1 after challenge whereas the number of Tregs in the draining lymph nodes peaks at day 2. As expected, depletion of Tregs by injection of a monoclonal antibody to CD25 prior to sensitization, led to a prolonged Acyl CoA dehydrogenase and sustained inflammatory response which was dependent on CD8 T cells, and co-stimulatory blockade with CTLA4-Ig suppressed the exaggerated inflammation. In contrast, blockade of the IL-10-receptor (IL-10R) did not further increase the exaggerated inflammatory response in the Treg-depleted mice. In the absence of Tregs, the response changed from a mainly acute reaction with heavy infiltration of neutrophils to a sustained response with more chronic characteristics (fewer neutrophils and dominated by macrophages).

In conclusion, strictly optimized in-house ABA-ELISA on 90 Japane

In conclusion, strictly optimized in-house ABA-ELISA on 90 Japanese isolates showed that the MBS of BabA, but not SabA, was significantly greater in the cancer than in the non-cancer group, and that BabA-high-binding isolates were associated with high average SabA MBS, which might correlate with the severity of gastric disorders, including gastric cancer. Evaluation of MBS of thes two adhesins, BabA and SabA, would be helpful in understanding and predicting damage to the stomach infected with H. pylori. This work was supported in part by a research grant from Shimonoseki-shi Cytopathology Study Group and by the Project Research Fund from the Kochi University. “
“The extracellular adherence protein (Eap)

from Staphylococcus aureus has been suggested as a vaccine candidate and for therapeutic use due to Paclitaxel its immunomodulating and antiangiogenic properties; however, little is PLX4032 known about anti-Eap antibodies in humans. We determined anti-Eap antibody titers by enzyme-linked immunosorbent assay and Western blot and measured serum samples from 92 patients with proven S. aureus infections and 93 healthy controls. The functionality of antibodies was assessed by a phagocytosis assay using Eap-coated fluorescent microspheres. Antibodies were detected in all human samples, but not in mice. Patients showed significantly higher titers than controls [immunoglobulin M (IgM), P=0.007;

IgG, P<0.0001]. Patients with deep or severe infections showed higher titers than those with superficial or mild disease. Eap alone was sufficient to promote phagocytosis by peripheral blood mononuclear cell and granulocytes that was moderately enhanced in the presence of human serum, but no correlation was found with the levels of anti-Eap antibodies. Anti-Eap antibodies are prevalent in all tested humans and correlate with the severity of S.

aureus infection; however, they do not seem to provide protection against invasive infections. Before considering Eap for therapy or as a vaccine candidate, further studies are warranted to assess the impact of the interference between Eap and its specific antibodies. Staphylococcus aureus-mediated infections are commonly found within the hospital and in the community (Grady & Cullen, 2003), ranging Idoxuridine from superficial skin pustules to life-threatening conditions such as osteomyelitis, endocarditis and sepsis (Lowy, 1998). Among a high number of virulence factors, the extracellular adherence protein (Eap), a 45–70 kDa molecule of the group of secreted expanded repertoire adhesive molecules (SERAM), has been studied intensively over the past few years (Haggar et al., 2003; Athanasopoulos et al., 2006; Xie et al., 2006; Schneider et al., 2007; Cheng et al., 2009; Wang et al., 2010). Recently, we showed significantly enhanced transcription of eap in S. aureus from infected human wounds compared with the transcription in vitro, with deeper wounds showing higher transcription then superficial wounds (Joost et al., 2009).

Thus microbial cdiGMP (3′-5′ linked) and endogenous 2′3′-cGAMP ma

Thus microbial cdiGMP (3′-5′ linked) and endogenous 2′3′-cGAMP made by cGAS are distinct CDN isotypes that both activate STING to trigger IFN-β release. CDNs generated by cGAS activate UNC51-like kinase (ULK1/ATG1), which inactivates STING to prevent sustained signaling during autophagy [18]. These developments raise key unresolved questions regarding

(i) optimal DNA isoforms that activate cGAS and other cytosolic DNA sensors, (ii) cell-type specificity of functional DNA sensing activity, and (iii) STING mutations and Atezolizumab purchase regulatory mechanisms that affect DNA and CDN sensing to stimulate IFN-β, especially in humans [19]. Immunogenic DNA is also dangerous, as shown by studies with mice lacking the DNA repair enzymes DNAseII or Trex-1; these mice developed lethal hyper-inflammatory or autoimmune syndromes due to sustained cytosolic DNA sensing via STING, which induced chronic IFN-β production [7, 8]. These studies provide striking demonstrations of the inherent potential to induce life-threatening autotoxicity, in this case due to innate DNA immunogenicity. A key issue is the source of immunogenic DNA in sterile tissues in the absence of inflammatory stimuli. Dying cells are the https://www.selleckchem.com/products/BI6727-Volasertib.html obvious

source as cells die constitutively, even in healthy tissues, due to finite cell longevity and mechanical or metabolic stress associated with normal tissue function or tissue remodeling. However, it is unclear how DNA from dead or dying cells accesses the cytoplasm of other cells that can sense cytosolic DNA to activate the STING/IFN-β pathway. Inflammatory insults such as infections, tumor growth, and tissue wounding, which enhance cell death, amplify opportunities to sense DNA and induce immunity, but also lower the tolerance barriers that prevent autoimmunity. Degrading DNA [7] and attenuating STING signaling are two ways to suppress chronic DNA sensing in sterile tissues, but another way to prevent autotoxicity may be to stimulate regulatory ISGs, for example the tryptophan catabolizing enzyme IDO, which reinforce tolerogenic processes in homeostatic and inflammatory settings. The crucial

need to allow immunity to infections Buspirone HCl to manifest on one hand, while maintaining self-tolerance on the other, suggests that cytosolic DNA sensing may incite both immunogenic and tolerogenic responses to “foreign” and “self” DNA. From an immunologic perspective, the key point is that DNA is an inherently “dangerous” biomolecule and responses to DNA must be finely tuned to match particular physiologic circumstances. Some ISGs stimulate immunity whereas other ISGs, such as IDO, have been shown to suppress immunity. A recent comprehensive survey of responses to 14 human DNA and RNA viruses identified a central role for cGAS in triggering ISG responses [20], indicating that cytosolic DNA sensing is pivotal in elaborating host responses to DNA and RNA virus infections.

11 Flash pulmonary oedema (FPE) is probably the most widely accep

11 Flash pulmonary oedema (FPE) is probably the most widely accepted indication for renal revascularization. Cardiac dysfunction and ARVD go hand in hand, which, coupled with other factors, predisposes to FPE. Renal artery constriction can cause hypertension mediated predominantly by the renin-angiotensin-aldosterone system (RAAS).41 A normally functioning contralateral kidney can Navitoclax respond to increased RAAS activity on the affected side by suppression of its own renin secretion to help prevent

volume overload. Should both kidneys be affected by RAS then this homeostatic safety valve will not function leading to higher risk of volume overload. Neurohormonal mediated endothelial dysfunction brought about by PD-0332991 nmr excess stimulation of the RAAS causes increased pulmonary capillary permeability and further contributes towards FPE.42 Additionally, CKD is associated with increased arterial stiffness,43 concentric left ventricular hypertrophy,44 and increased left ventricular stiffness.45 This triad makes the circulatory system exquisitely sensitive to alterations in volume state, with little physiological reserve to deal with volume expansion. In the setting of FPE, ARVD is, predictably, often bilateral or present in a solitary functioning kidney. Although there are no

randomized or observational studies, revascularization has been shown to be of benefit in small series and case reports,46,47 with a suggestion that those with bilateral disease are most likely to benefit.48 Resistant hypertension (RH), defined as uncontrolled blood pressure (>160/90 mmHg) despite use of three or more

antihypertensive medications, is an area of ongoing debate. Therapeutic measures to treat hypertension have evolved rapidly over the years, and many drug therapies are applicable in patients with ARVD. Given the relationship between untreated hypertension and deterioration of renal function, effective treatment is paramount. While previously nephrectomies of ischaemic kidneys were undertaken to treat ‘malignant’ hypertension,49 with the Cyclin-dependent kinase 3 advent of antihypertensives targeted to block the RAAS, and percutaneous revascularization techniques, this approach is now no longer applicable. Despite these pharmacological advances, there is often reticence to use angiotensin converting enzyme inhibitors (ACEi) and receptor blockers (ARB). These are very effective treatments for renovascular driven hypertension but there are widely held beliefs that bilateral RAS is a contra-indication for their use. Although it is beyond dispute that ACEi or ARB use can reduce GFR in certain individuals, patients with unilateral disease and a normally functioning contralateral kidney do not usually suffer this fate.50 Indeed, our experience is that many patients with significant bilateral RAS can tolerate RAAS blockade without detriment to function.